Moreover, a combination of classical non-steroideal anti-inflammatory drugs aimed at inhibiting COX-2 and Triacsin C targeting ACSL4 has shown a synergistic pro-apoptotic effect in the colon cancer cell line HT29 [21]. Here, ACSL4 is linked to colonic neoplasm.